Adagene (ADAG) Competitors

Adagene (NASDAQ:ADAG) and NGM Biopharmaceuticals (NASDAQ:NGM) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, community ranking, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.

Which has higher valuation and earnings, ADAG or NGM?

Adagene has higher revenue and earnings than NGM Biopharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adagene	$18.11M	6.16	-$18.95M	N/A	N/A
NGM Biopharmaceuticals	$4.42M	29.10	-$142.38M	-$1.72	-0.90

Do institutionals and insiders hold more shares of ADAG or NGM?

9.5% of Adagene shares are held by institutional investors. Comparatively, 75.7% of NGM Biopharmaceuticals shares are held by institutional investors. 21.2% of Adagene shares are held by insiders. Comparatively, 35.9% of NGM Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Does the MarketBeat Community believe in ADAG or NGM?

NGM Biopharmaceuticals received 14 more outperform votes than Adagene when rated by MarketBeat users. However, 78.26% of users gave Adagene an outperform vote while only 60.38% of users gave NGM Biopharmaceuticals an outperform vote.

Company	Underperform	Outperform
Adagene	Outperform Votes 18 78.26%	Underperform Votes 5 21.74%
NGM Biopharmaceuticals	Outperform Votes 32 60.38%	Underperform Votes 21 39.62%

Which has more risk & volatility, ADAG or NGM?

Adagene has a beta of 0.44, suggesting that its stock price is 56% less volatile than the S&P 500. Comparatively, NGM Biopharmaceuticals has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500.

Does the media favor ADAG or NGM?

In the previous week, NGM Biopharmaceuticals had 1 more articles in the media than Adagene. MarketBeat recorded 1 mentions for NGM Biopharmaceuticals and 0 mentions for Adagene. Adagene's average media sentiment score of 1.34 beat NGM Biopharmaceuticals' score of 0.00 indicating that Adagene is being referred to more favorably in the media.

Company	Overall Sentiment
Adagene	Positive
NGM Biopharmaceuticals	Neutral

Do analysts prefer ADAG or NGM?

Adagene currently has a consensus target price of $5.00, suggesting a potential upside of 97.63%. NGM Biopharmaceuticals has a consensus target price of $3.68, suggesting a potential upside of 139.18%. Given NGM Biopharmaceuticals' higher probable upside, analysts clearly believe NGM Biopharmaceuticals is more favorable than Adagene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adagene	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
NGM Biopharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Is ADAG or NGM more profitable?

Adagene has a net margin of 0.00% compared to NGM Biopharmaceuticals' net margin of -3,223.34%. Adagene's return on equity of 0.00% beat NGM Biopharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adagene	N/A	N/A	N/A
NGM Biopharmaceuticals	-3,223.34%	-77.85%	-67.76%

Summary

Adagene beats NGM Biopharmaceuticals on 9 of the 16 factors compared between the two stocks.